Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts.
about
Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primatesCell-targeting antibodies in immunity to EbolaRationally Designed TLR4 Ligands for Vaccine Adjuvant DiscoveryNonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesA Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral ImmunityRationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPsMucosal Immunogenicity of Genetically Modified Lactobacillus acidophilus Expressing an HIV-1 Epitope within the Surface Layer Protein.Discrete partitioning of HIV-1 Env forms revealed by viral capture.High Antibody-Dependent Cellular Cytotoxicity Antibody Titers to H5N1 and H7N9 Avian Influenza A Viruses in Healthy US Adults and Older Children.Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates.Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine.Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
P2860
Q21559476-E256B115-CDF8-4607-84CB-C4B566B3C393Q28068972-DC323E92-F448-4605-A851-72E0C514DA84Q33654530-D06CE936-B780-413A-9179-9EEA80C09381Q34057711-FB25BB0E-2B63-47C6-A639-B4C86431E203Q34520389-D21E8416-7690-4229-92E7-5C29FF336F47Q34540352-64DF5345-21D1-49CA-8389-0ACD61859F67Q35675647-F2D572FA-4C06-496D-9C09-5C85560FBD5AQ35824311-92EEA3E9-64A8-490C-A221-4E0EF2CD3EDAQ36088254-F15FF33D-774C-4343-A654-611E709C23DDQ36344790-68A3673F-F96D-4C4E-83F8-D8D5E924837CQ38602178-F0EA30A9-C14E-48E3-BDF0-BCB1542D424BQ40062330-C82C44BE-016A-4093-823C-7A9027115BDAQ40295939-0906B740-B925-450A-BA4F-8C0A3FE28ECBQ42368984-F74EF0CE-8790-44C5-BF13-5E74E5F0CC01Q47147105-91F1644E-105F-46E5-AA34-6222048EB4ADQ56558172-A8C12CA5-F2CD-49EC-9865-3EC006061B96
P2860
Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Protective antiviral antibodie ...... nts and evolution of concepts.
@en
type
label
Protective antiviral antibodie ...... nts and evolution of concepts.
@en
prefLabel
Protective antiviral antibodie ...... nts and evolution of concepts.
@en
P1433
P1476
Protective antiviral antibodie ...... nts and evolution of concepts.
@en
P2093
Alan L Schmaljohn
P304
P356
10.2174/1570162X113116660057
P577
2013-07-01T00:00:00Z